UniQure Down in Premarket as FDA Says Huntington's Gene-Therapy Data Falls Short
By Adriano Marchese
UniQure shares fell in premarket trading Monday after the Food and Drug Administration said the company's data isn't strong enough to show its Huntington's disease gene therapy is effective.
Shares traded 42% lower ahead of the morning bell at $9.
The gene-therapy company said Monday that the FDA stated that it can't agree that data from the Phase I/II studies, compared with an external control, provide enough primary evidence of effectiveness required to support a marketing application for the drug AMT-130.
Huntington's disease is an inherited and progressive neurodegenerative disorder that is caused by faulty genes triggering the breakdown of nerve cells in the brain.
UniQure said the regulator is urging the company to run a more rigorous trial that includes randomized, double-blind, sham surgery-controlled study.
The company said it intends to keep working with the FDA on what a Phase III program should look like and plans to request a type B meeting in the second quarter of 2026 to discuss possible study designs.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
March 02, 2026 08:13 ET (13:13 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Sell for Tax-Loss Harvesting
33 Undervalued Stocks to Buy Before the Market Shifts Again
What’s Ahead for Stocks This Quarter—and Where to Invest
Ask the Analyst: What Is the Best Source for Low-Risk Tax-Free Income?
United States